Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 18th, 2026

LECO_Weekly-Healthcare-News_5-18-2026-1Download
  1. Boston Scientific Announces $1.5 billion Strategic Investment in MiRus LLC Boston Scientific Corporation (NYSE: BSX) announced a $1.5 billion strategic investment for an approximately 34% equity stake in MiRus LLC, a privately held company developing proprietary biomaterials, implants, and procedural solutions for cardiovascular and orthopedic diseases. Announced May 18, 2026, the agreement includes an exclusive option to acquire MiRus’ SIEGEL™ Balloon Expandable TAVR system, with potential additional payments of up to $3 billion upon clinical and regulatory milestones. The nickel-free, rhenium-alloy valve features a smaller delivery sheath, precise placement, and promising early clinical results in the ongoing STAR pivotal trial. The investment strengthens Boston Scientific’s interventional cardiology portfolio in the rapidly growing aortic stenosis market. (Link)
  2. J.P. Morgan, KKR, BofA Securities, and Barclays led the $478.7 million initial public offering of GMR Solutions (NYSE: GMRS) at a revised price of $15 per share GMR Solutions (NYSE: GMRS), the largest provider of emergency medical services in the U.S., priced its IPO at $15 per share, raising $478.7 million. The offering was led by a major syndicate including J.P. Morgan and KKR, with the latter also providing a $500 million concurrent private placement to bolster the company’s balance sheet. GMR Solutions plans to use the IPO proceeds primarily to pay down its existing debt. Despite the offering price being lowered from initial expectations, the IPO values the company at approximately $3.4 billion. The deal highlights significant institutional interest in the stabilization and growth potential of essential emergency and transport healthcare services. (Link)
  3. Prestige Consumer Healthcare (NYSE:PBH) Announces Acquisition of LaCorium Health Prestige Consumer Healthcare Inc. has entered into a definitive agreement to acquire LaCorium Health, a leading Australian platform in therapeutic skin care, lip, foot, and skin treatments. Announced May 13–14, 2026 alongside fiscal results, the approximately $150 million cash deal adds a high-growth, asset-light international OTC portfolio with strong market positions and expected double-digit revenue growth. The acquisition enhances Prestige’s dermatological offerings and geographic diversification. (Link)
  4. Lumexa Imaging (NASD: LMRI) executed its growth strategy by adding four new centers through joint ventures with University of Pittsburgh Medical Center (UPMC) and Advocate Health Lumexa Imaging the addition of four new locations in 2026, advancing its strategy to expand in high-growth markets via strategic partnerships. The expansion includes entry into the Pennsylvania market through a joint venture with the University of Pittsburgh Medical Center (UPMC) and further growth in the Southeast with Advocate Health. These additions, consisting of two acquisitions and two de novo centers, bring Lumexa’s total to over 190 outpatient imaging centers. The company leverages these joint ventures for capital efficiency and repeatability, focusing on the sustained shift toward outpatient, lower-cost sites of care driven by an aging population. (Link)
  5. Coastal Medical Transportation Systems Acquires Alert Ambulance to Expand New England Regional Care Network Coastal Medical Transportation Systems (CMTS), a leading privately owned medical transportation provider in New England, has completed the acquisition of Alert Ambulance Service. Announced May 18, 2026, the deal further strengthens CMTS’s position as one of the largest and most comprehensive ambulance and medical transportation providers in the region, following its prior integration of Fallon and Lifeline Ambulance Services. The acquisition expands geographic coverage across Massachusetts, New Hampshire, and Rhode Island, increases fleet size to over 325 vehicles, and grows the combined workforce to nearly 1,500 clinicians and support staff. (Link)
  6. Wellgistics Health (NASD: WGRX) Accelerates Digital Health Expansion with Planned Acquisition of WellCare Today Wellgistics Health, Inc. announced a non-binding letter of intent to acquire WellCare Today, a remote monitoring company specializing in RPM, RTM, and CCM programs powered by Samsung Galaxy Watch technology. Announced May 14, 2026, the proposed ~$15 million transaction (including $3 million cash and performance-based earnout in preferred stock) will integrate WellCare Today’s HealthAssist® platform with Wellgistics’ MSO pilot through Kare Clinicals and its network of over 6,500 independent pharmacies. The combination aims to enhance patient engagement, medication adherence, chronic care management, and reimbursement opportunities through wearable-enabled remote monitoring. (Link)
  7. Lorient Capital entered a strategic growth partnership with PeterMD to accelerate the national expansion of its proactive Medicine 3.0 healthcare platform Lorient Capital, a private equity firm exclusively focused on healthcare, has made a strategic investment in PeterMD to scale its personalized “Medicine 3.0” platform. PeterMD specializes in precision medicine, offering customized hormone health, longevity, and sexual wellness treatments through advanced diagnostics and proactive care. Lorient Capital is deploying capital from its $500 million Healthcare Fund III to fuel PeterMD’s national growth, aiming to transform the traditional reactive healthcare model. The partnership focuses on enhancing clinical outcomes and operational efficiency as PeterMD seeks to expand its footprint and bring precision-based integrated medicine to a broader national patient base. (Link)
  8. Blackstone and KKR & Co. Inc. reached a restructuring deal to take over the dental firm Affordable Care after slashing its total debt by 70% Direct lenders Blackstone and KKR are set to take control of Affordable Care, one of the largest U.S. dental services providers, following a major debt restructuring. The deal involves the lenders in a $1.4 billion private credit structure swapping their debt for equity, effectively slashing the dental firm’s debt load by approximately 70%. This restructuring provides Affordable Care with a significantly improved balance sheet to manage its extensive network of dental practices. The move underscores the increasing trend of major private credit lenders like Blackstone and KKR transitioning from creditors to equity owners to stabilize and preserve value in distressed healthcare portfolios. (Link)
  9. Quince Therapeutics (NASDAQ: QNCX)  Acquires Orphai Therapeutics and Raises up to $187 Million in Private Placement to Advance Pulmonary Pipeline Quince Therapeutics, Inc. announced the acquisition of Orphai Therapeutics, bringing in LAM-001, an inhaled formulation of rapamycin (sirolimus) for rare pulmonary diseases including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). Concurrently, Quince entered a private placement to raise up to $187 million ($115 million upfront + up to $72 million from warrants), led by Balyasny Asset Management with participation from a strong syndicate of healthcare investors. The combined proceeds are expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2 data readouts in 2027 and 2028.
  10. Orthopaedic Specialty Group and OrthoConnecticut Merge to Create Statewide Physician-Led Platform Powered by HOPCo Technology Partnership Orthopaedic Specialty Group (OSG) and OrthoConnecticut have officially merged, creating a dominant, physician-led musculoskeletal (MSK) care platform across Connecticut. The merger is bolstered by a strategic partnership with Healthcare Outcomes Performance Company (HOPCo), the global leader in MSK value-based care. While the organizations merge their clinical networks to improve patient access, HOPCo provides the digital infrastructure, including advanced analytics and care management tools, to optimize outcomes and reduce total care costs. This collaboration allows the unified practice to scale thoughtfully while preserving clinical autonomy and delivering high-quality orthopedic services closer to home for patients throughout the Connecticut. (Link)
  11. Sweetser merged with Common Ties Mental Health Services to create Maine’s largest provider of Certified Community Behavioral Health Clinic services Common Ties Mental Health Services, based in Lewiston, has officially merged with Sweetser to create a robust behavioral health network in Maine. This merger establishes Sweetser as the state’s largest provider of Certified Community Behavioral Health Clinic (CCBHC) services, integrating Common Ties’ regional expertise into Sweetser’s broad statewide platform. The investment focuses on streamlining mental health delivery, expanding free community training, and increasing access to specialized behavioral health services. By consolidating resources, the combined entity aims to build a more sustainable and accessible care model to address the rising mental health needs across Maine’s diverse and often underserved communities. (Link)
  12. Gryphon Investors-backed LEARN Behavioral acquired Little Leaves Behavioral Services from FullBloom, a portfolio company of American Securities LEARN Behavioral, a leading autism therapy provider backed by Gryphon Investors, has acquired Little Leaves Behavioral Services from FullBloom. FullBloom is a portfolio company of American Securities and sold the division to refocus on its core educational services. Little Leaves operates 18 early-intervention centers across Maryland, Virginia, and Florida, which will now join LEARN’s extensive national network. This acquisition allows LEARN Behavioral to expand its density in the Mid-Atlantic and establish a larger presence in the Florida market. The deal represents a significant consolidation within the ABA (Applied Behavior Analysis) sector, focusing on scaling early-intervention services for children with autism. (Link)
  13. Arcadea Group expanded its mission-critical software presence in Brazil through the acquisition of hemotherapy and hospital software provider Sofis Arcadea Group, a long-term investor in high-quality software firms, has acquired Sofis, a Rio de Janeiro-based provider of healthcare software. Sofis specializes in mission-critical solutions for blood bank management (hemotherapy) and hospital ERP systems, serving over 300 institutions across Brazil. This acquisition marks Arcadea’s fourth investment in the Brazilian healthcare technology market. Arcadea plans to leverage its permanent capital base to support Sofis’ long-term product development and international expansion. By transitioning from a founder-owned model to one backed by Arcadea’s global resources, Sofis aims to modernize its platform and deepen its penetration into the complex Latin American healthcare technology landscape. (Link)
  14. Iterative Health Acquires Cardiology Research Sites from NextStage Clinical Research Iterative Health, a healthcare technology and services company focused on accelerating clinical research, has acquired three cardiology research sites from NextStage Clinical Research in Texas (Beaumont, Port Arthur, and Waco). Announced on May 14, 2026, with Bourne Partners serving as financial advisor, the deal expands Iterative Health’s elite site network and strengthens its capabilities in cardiovascular research — a therapeutic area affecting nearly half of U.S. adults. The sites bring experienced teams, strong community provider connections, and an active trial portfolio, enhancing patient access to innovative therapies while providing sponsors with high-performing, real-world research centers. (Link)
  15. HealthScape Advisors Acquires PayerAlly to Strengthen Pharmacy Benefit Management Capabilities HealthScape Advisors, a leading payer advisory firm and a Chartis company, has acquired PayerAlly, an independent pharmacy consulting firm specializing in pharmacy benefit management (PBM) strategy, procurement, and optimization. Announced May 12, 2026 (with coverage extending through mid-May), the deal enhances HealthScape’s ability to help health plans and employers address rapidly rising prescription drug costs through integrated, clinically informed total cost-of-care solutions. PayerAlly’s expertise in PBM strategy complements HealthScape’s broader payer advisory platform, supporting more effective management of one of healthcare’s fastest-growing expense categories. (Link)
  16. NeuroVision Acquires Durin Life Sciences to Advance Neurodegenerative Diagnostics NeuroVision, a diagnostics company developing early detection tools for Alzheimer’s and other neurodegenerative diseases, has acquired Durin Life Sciences, a fellow diagnostics developer. Announced May 15, 2026, the deal adds Durin’s blood-based Duritect™ tests for early detection and monitoring of Alzheimer’s, Parkinson’s, and ALS. The combination accelerates NeuroVision’s platform for earlier, more accessible diagnosis and disease management, addressing critical gaps in neurodegenerative care. (Link)
  17. IKS Health Acquires ARAI Solutions to Accelerate Agentic AI Capabilities IKS Health, a global leader in care enablement and AI-driven clinical solutions, has acquired ARAI Solutions, a specialized AI management and technology company focused on biomedical knowledge graphs and clinical reasoning infrastructure. Announced May 13–14, 2026, the deal enhances IKS Health’s ability to build proprietary small language models and agentic AI systems for clinical, operational, and revenue cycle workflows. ARAI’s ontology layer and applied research expertise will improve the reliability, auditability, and efficiency of IKS’s AI platforms serving health systems nationwide. (Link)
  18. Signant Health Acquires Ametris to Create End-to-End eCOA and Digital Outcome Measures Platform Signant Health, a leading evidence generation company for clinical trials, has acquired Ametris (formerly ActiGraph), a global digital health solutions provider specializing in wearable-derived clinical outcome measures. The deal integrates Signant’s eCOA (electronic Clinical Outcome Assessment) solutions with Ametris’ validated sensor-based technologies for objective measurement of physical activity and function. The combined platform will deliver multimodal evidence—patient-reported outcomes alongside continuous real-world data—simplifying complex trials, accelerating insights, and strengthening regulatory submissions, particularly in CNS and other therapeutic areas. (Link)
  19. iSpecimen Inc. (NASD: ISPC) Secures $2.5 Million Private Placement to Support Operations Amid 89% Annual Stock Decline iSpecimen Inc. finalized a $2.5 million private placement on May 11, 2026, to bolster working capital. The biospecimen marketplace provider, currently valued at $3.39 million, has seen its share price plummet 89% over the past year to $4.57. This funding follows a $5.5 million raise in late 2025, aimed at mitigating rapid cash burn. iSpecimen, which connects medical researchers with specimen providers, will use the proceeds for general corporate purposes as it navigates significant financial challenges and seeks to stabilize its market position. (Link)
  20. Blue Sea Capital supported One Physics in its strategic acquisition and partnership with Petrone Associates to expand its Northeast clinical services footprint One Physics, the largest outsourced medical physics services company in North America, has announced its 22nd acquisition with the addition of New York-based Petrone Associates. This strategic move, backed by growth-oriented private equity firm Blue Sea Capital, significantly strengthens One Physics’ presence in the New York City metropolitan market and Northern New Jersey. The partnership leverages One Physics’ national scale and Petrone’s established clinical reputation to provide comprehensive diagnostic and therapy medical physics, radiation safety, and dosimetry services. Blue Sea Capital, managing over $1.5 billion in assets, remains committed to accelerating One Physics’ industry leadership through continued regional consolidation. (Link)

Venture Deals and Other

  1. Sound Ventures, Alumni Ventures, Link Ventures, Redesign Health, and RRE Ventures invested $17 million in Anomaly Insights to address healthcare payer-provider information asymmetry. Anomaly Insights, an AI-powered payer intelligence firm, secured $17 million in funding led by Sound Ventures to combat the informational gap between healthcare payers and providers. The investment includes participation from RRE Ventures and Redesign Health, focusing on Anomaly’s real-time AI platform that identifies and corrects billing errors and payment inaccuracies. The company aims to reduce the massive administrative waste in the U.S. healthcare system by providing transparency in the claims process. This new capital will be used to enhance Anomaly’s machine learning models and scale its solutions across larger health systems and insurance networks to streamline payment cycles. (Link)
  2. McKesson Ventures, FCA Venture Partners, Sanofi Ventures, and AIX Ventures led a $26 million Series A for Branchlab to scale its AI-driven biopharma commercialization platform Branchlab raised $26 million in a Series A round led by McKesson Ventures to accelerate the growth of its Pathwai™ platform. The round, which included corporate venture backing from Sanofi Ventures, brings Branchlab’s total funding to $35 million. The company uses privacy-first AI to optimize the patient journey and enhance pharmaceutical commercialization, reporting a 70% increase in patient activation efficiency. Branchlab intends to use the capital to expand its engineering and data science teams in New York and Colorado. By providing real-time insights to biopharma brands, Branchlab aims to make pharmaceutical marketing more effective and patient-centric through advanced data analytics. (Link)
  3. AIX Ventures led a $2 million pre-Seed funding round for Chromie Health to develop its autonomous AI-powered hospital workforce management platform Chromie Health, a New York-based startup, secured $2 million in pre-Seed funding led by AIX Ventures to tackle the hospital staffing crisis. The company develops autonomous AI agents that automate complex administrative tasks and workforce scheduling without requiring deep IT integration. Chromie Health’s platform is designed to alleviate the burnout of clinical staff by handling the logistics of hospital operations through intelligent automation. The investment will support the development of additional “digital agents” capable of reasoning through clinical context and staffing needs. This seed capital positions Chromie Health to pilot its solutions across more health systems seeking to modernize their operational efficiency. (Link)
  4. Blueprint Equity, Villain Capital, Z21 Ventures, and Bienville Capital led a $14 million growth funding round for pediatric-focused AI operating system Develo Develo, an AI-native operating system for pediatric practices, raised $14 million in a funding round led by Blueprint Equity. The platform integrates clinical workflows, billing, and parent engagement into a single AI-driven ecosystem, currently serving hundreds of providers across 25 states. The capital will be used to accelerate the development of specialized AI tools, including automated charge capture and AI-assisted scribing for pediatricians. Develo aims to reduce the administrative burden that leads to physician burnout while improving the financial performance of independent pediatric practices. The investment highlights a growing trend toward specialty-specific AI platforms that address unique clinical and operational workflows. (Link)
  5. Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC backed Forus with $160 million to build its AI-powered pharmaceutical delivery network Forus, formerly known as Tandem, raised $160 million in a major funding round backed by top-tier venture firms including Thrive Capital and General Catalyst. The company is building an AI-powered infrastructure that connects doctors, pharmacies, and biopharma companies to streamline the drug fulfillment process. Forus automates the “last-mile” clinical steps, such as insurance authorizations, to ensure patients receive treatments faster. With five of the top ten global biopharma companies already utilizing the network, Forus plans to use the investment to expand its nationwide reach and further integrate its AI layer into existing physician and pharmacy workflows to eliminate treatment delays. (Link)
  6. Uncork Capital, Frist Cressey Ventures, Moxxie Ventures, and Coalition Operators provided $11.6 million in Seed funding for the launch of Knit Health’s clinical behavior AI Knit Health, a spin-out from UC Berkeley, launched with $11.6 million in Seed funding co-led by Uncork Capital and Frist Cressey Ventures. The company is developing a Large Clinical Behavior Model (LCBM) trained on real-world clinician decisions across 30 U.S. health systems. Knit Health’s AI agents are designed to handle triage, patient flow, and care coordination by learning from collective clinical experience rather than just static text. The funding will be used to scale its foundational intelligence layer and deploy AI agents that assist in high-stakes hospital environments. This investment reflects a shift toward “Action AI” that can reason and perform complex tasks in clinical settings. (Link)
  7. Salesforce Ventures, Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures raised $17.5 million in Series A funding for Optura’s AI governance platform Optura, a Nashville-based healthcare AI governance platform, secured $17.5 million in Series A funding led by Salesforce Ventures. The investment, which brings Optura’s total funding to $25 million, will support the expansion of its “Return on AI Investment” (ROAI) platform. Optura helps enterprise healthcare organizations, such as Independence Blue Cross, map fragmented data and measure the efficacy of their AI agents. The capital will be used to scale partnerships with LLM providers and grow its engineering teams. By providing a unified knowledge layer, Optura enables healthcare leaders to prioritize AI use cases based on actual operational readiness and projected business value. (Link)
  8. Norwest, Primary, Next Ventures, Constellation, and Scrub Capital led a $25 million financing round for Tokaido Health to launch its AI medication steerage platform. Tokaido Health emerged from stealth with $25 million in funding led by Norwest and Primary to address skyrocketing pharmacy costs for employers. The platform utilizes AI and behavioral economics to identify same-or-better medications that cost less, steering members toward high-value options like biosimilars. Tokaido layers on top of existing PBM stacks, allowing for a seamless integration without plan redesigns. The investment will be used to scale its concierge-style member outreach and expand its clinical reasoning engine. By focusing on site-of-care steerage and polypharmacy reconciliation, Tokaido aims to eliminate billions in wasted drug spending while improving the patient experience. (Link)
  9. Andera Partners, American Century Investments, Clarevia Ventures, Time BioVentures, View Ventures, Cadence Healthcare Ventures, and Anduril Investors led a $20 million Series D for Rivermark Medical Rivermark Medical, a urology-focused medical device company, raised $20 million in Series D funding led by Andera Partners. The financing will support the ongoing RAPID III pivotal clinical trial for the FloStent™ System, a non-surgical treatment for men with benign prostatic hyperplasia (BPH). The investment syndicate includes American Century Investments and Time BioVentures, focusing on bringing this reversible, office-based therapy to market. The FloStent is designed to be easily adjustable and tissue-preserving, offering a first-line alternative to more invasive surgical procedures. The capital will also be used to prepare for a U.S. commercial launch following expected regulatory approval. (Link)
  10. Aulis Capital led a $13.4 million Seed funding round for Shyld AI to accelerate the deployment of its autonomous AI-driven infection control solutions Shyld AI, a healthcare technology company, secured $13.4 million in Seed funding led by Aulis Capital to expand its active intelligence solutions for hospital facilities. Shyld AI develops autonomous physical agents that use AI and UV disinfection to reduce environmental contamination in high-risk areas like operating rooms. The funding will accelerate deployments across U.S. health systems and support the company’s expansion into regulated pharmaceutical manufacturing environments. By streamlining infection control and compliance without adding to the workload of hospital staff, Shyld AI aims to improve patient safety and operational efficiency. The investment marks a significant milestone in the adoption of autonomous hygiene agents in healthcare. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities
CLICK HERE